The CEO of Novartis has raised alarms about the potential consequences of Trump's drug pricing policy, suggesting it could create a challenging landscape for both drugmakers and patients.
This warning comes amid the sentencing of Purdue Pharma, which continues to draw attention to ongoing issues within the pharmaceutical industry.
As industry leaders voice their concerns, the future of drug pricing remains uncertain, highlighting the need for careful consideration of policy impacts.